New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
10:04 EDTTGTXTG Therapeutics falls 13.9%
TG Therapeutics is down 13.9%, or $1.23, to $7.59
News For TGTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2014
05:57 EDTTGTXTG Therapeutics price target raised to $22 from $19 at Brean Capital
Brean Capital raised its price target for TG Therapeutics shares to $22 after the company acquired the rights to TGR-1202 from Rhizen Pharmaceuticals. The firm keeps a Buy rating on the stock.
September 23, 2014
07:34 EDTTGTXTG Therapeutics announces exercise of license option for TGR-1202
TG Therapeutics announced that it has exercised its option to license the global rights to TGR-1202, the company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A. The company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the company's license option. In exchange for the global license, Rhizen will receive a one-time, upfront cash payment of $4M and approximately 370,000 shares of TG Therapeutics' common stock. TG Therapeutics will receive exclusive worldwide rights, excluding India, for the development and commercialization of TGR-1202 for all indications. Rhizen will be eligible to receive regulatory filing, approval and sales based milestones in the aggregate of approximately $240M, and tiered royalties based on net sales.
September 16, 2014
10:30 EDTTGTXTG Therapeutics capitlal raise unlikely, says Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use